# US 2014/0271461 A1 · Compositions and associated methods for radioisotope-binding microparticles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0271461 A1
- Document ID: US20140271461A1
- Status: Published application
- Kind: A1
- Application number: 14/207,219
- Filed: 2014-03-12
- Published: 2014-09-18
- Earliest claimed: 2013-03-13
- Assignees: Biosphere Medical, Inc.
- Applicants: Biosphere Medical, Inc.
- Inventors: Philippe Reb; Celine Chaix
- Web page: https://patentgrep.com/patent/US20140271461A1

## CPC

- A61K 51/1244: {microparticles or nanoparticles, e.g. polymeric nanoparticles}
- A61P 35/00: Antineoplastic agents
- Y10T 428/2982: Particulate matter [e.g., sphere, flake, etc.]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

The present disclosure relates to polymeric materials that may be labeled with a radioisotope, to processes for producing the labeled polymeric material, and to methods of using the materials in analytical and therapeutic applications. Specifically, the disclosure relates to injectable and implantable microparticles, such as microspheres, which are associated with radioisotopes such that the microparticles are both therapeutic and detectable. The radioisotope-containing microparticles are useful for embolization and other therapeutic medical applications.

## Claims

### Claim 1

A microparticle, comprising a polymer having a diameter ranging from about 1 micrometer to about 2000 micrometer, the polymer comprising at least one type of polymerized monomer and a chelating agent, the chelating agent configured to chelate a radioisotope.

### Claim 2 (depends on 1)

The microparticle of claim 1, wherein the microparticle is a microsphere.

### Claim 3 (depends on 1)

The microparticle of claim 1, wherein the polymer comprises one or more polymerized monomer selected from at least one of the following: acrylate, acrylamide, acrylic, vinyl, acetal, allyl, cellulosic, methacrylate, polyamide, polycarbonate, polyester, polyimide, polyolefin, polyphosphate, polyurethane, silicone, styrenic, and polysaccharide.

### Claim 4 (depends on 1)

The microparticle of claim 1, wherein the polymer comprises one or more polymerized monomer selected from at least one of the following: N-[tris(hydroxymethyl)methyl]-acrylamide and sodium acrylate.

### Claim 5 (depends on 1)

The microparticle of claim 1, wherein the chelating agent comprises mercaptoacetyltriglycine or a mercaptoacetyltriglycine derivative.

### Claim 6 (depends on 1)

The microparticle of claim 1, wherein the chelating agent comprises a compound of Formula I:
wherein n is between 1 and 18, inclusive;
Xa and Xb may independently be O, S or N; and
R may be alkyl or H.

### Claim 7 (depends on 1)

The microparticle of claim 1, wherein the radioisotope is both a β- and γ-emitter.

### Claim 8 (depends on 7)

The microparticle of claim 7, wherein the radioisotope is 186Re or 188Re.

### Claim 9 (depends on 1)

The microparticle of claim 1, wherein the microparticle is an embolic microsphere.

### Claim 10 (depends on 1)

The microparticle of claim 1, wherein the polymer comprises one or more polymerized monomer selected from at least one of the following: N-[tris(hydroxymethyl)methyl]-acrylamide and sodium acrylate; wherein the chelating agent is mercaptoacetyltriglycine or a mercaptoacetyltriglycine derivative, and wherein the radioisotope is 186Re or 188Re.

### Claim 11 (depends on 1)

The microparticle of claim 1, wherein the radioisotope is not leached from the microparticle to an extent greater than about 3% of its original level by weight over a period of three months.

### Claim 12 (depends on 2)

The microsphere of claim 2, wherein the diameter of said microsphere ranges from between about 10 micrometers to about 200 micrometers.

### Claim 13

A microparticle of Formula II:
P—X-M (Formula II)
wherein P is a polymer comprising polymerized monomers selected from at least one of the following: acrylates, acrylamides, acrylics, vinyls, acetals, allyls, cellulosics, methacrylates, polyamides, polycarbonates, polyesters, polyimides, polyolefins, polyphosphates, polyurethanes, silicones, styrenics, and polysaccharides;
wherein X represents Y—Z,
wherein Z is a chelating group selected from at least one of the following: mercaptoacetyltriglycine; a mercaptoacetyltriglycine derivative; EDTA; an EDTA derivative including EGTA, BAPTA, DOTA, DTPA-monoamide, DO3A, NOTA-Bn, NODASA, and NODAGA; a crown ether, iminodiacetic acid; styrene; butyl acrylate; glycidyl methacrylate; aminocarboxylic acids such as alkylenediamine-N,N,N′, N′-tetraacetic acid-(meth)acrylamide (MAM-EDTA); acrylic acid; butyl methacrylate; bromomethyl acrylate; α-chloromethacryloyl chloride; isonicotinyl hydrazone; 2-methacryloxy-5-methyl benzophenone; pyridoxal isonicotinyl hydrazone; peptides; oligomers; amino acids; phosphorodiamidate morpholino oligomers; dimercaptosuccinic acids; pentetic acid; hydroxyethylidine diphosphonate; 4-hexadecyl-2,2,9,9-tetramethyl-4,7-diaza-1,10-decanedithiol (HDD); an ethyl cysteinate dimer/lipiodol mixture; and a bis(diethyldithiocarbamato)nitrido (DEDC) chelator;
wherein Y comprises a chain of between 1-18 non-hydrogen atoms independently selected from at least one of C, N, O or S; and
wherein M is a radioisotope.

### Claim 14 (depends on 13)

The microparticle of claim 13, wherein the chelating agent comprises mercaptoacetyltriglycine or a mercaptoacetyltriglycine derivative.

### Claim 15 (depends on 13)

The microparticle of claim 13, wherein the chelating agent is covalently bound to the microparticle after the polymeric microparticle has been formed.

### Claim 16 (depends on 13)

The microparticle of claim 13, wherein the chelating agent comprises a compound of Formula I
wherein n is between 1 and 18, inclusive;
Xa and Xb may independently be O, S or N; and
R may be alkyl or H.

### Claim 17 (depends on 13)

The microparticle of claim 13, wherein the chelating agent is associated with the microparticle during polymerization of the microparticle.

### Claim 18 (depends on 1)

A method of preparing a radioisotope-labeled microparticle, comprising the steps of:
1) fabricating a microparticle according to claim 1, and
2) associating the resulting microparticle with a radioisotope.

### Claim 19 (depends on 18)

The method of claim 18, wherein fabricating the microparticle comprises polymerizing the chelating agent with the monomer, wherein the chelating agent comprises:
wherein n is between 1 and 18, inclusive;
Xa and Xb may independently be O, S or N; and
R may be alkyl or H.

### Claim 20 (depends on 1)

A method of treating a mammal suffering from a medical condition, comprising the step of administering to said mammal a therapeutically effective amount of a radioisotope-labeled microparticle according to claim 1.

### Claim 21 (depends on 20)

The method of claim 20, wherein the administering is via a therapeutic vascular embolization.

### Claim 22 (depends on 1)

A kit for performing a prophylactic or therapeutic treatment of a mammal suffering from a medical condition, wherein the kit comprises a sterile container and sterile and biocompatible polymeric microparticles according to claim 1, configured to be associated with a radioisotope and wherein the treatment comprising administering to the mammal a therapeutically effective amount of the radioisotope.
